Tscan Therapeutics Inc (TCRX NASDAQ) stock market data APIs
$1.8808
0.15(8.7%)
as of March 14, 2025
Tscan Therapeutics Inc Financial Data Overview
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation. It also advanced TS-102 into IND-enabling activities. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204, which are in Phase 1 clinical trial, for the treatment of solid tumors. It has collaborations with Novartis Institutes for BioMedical Research, Inc. to discover and develop novel TCR-T therapies; and Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease using TargetScan, a proprietary target discovery platform. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Prev. Close
1.7314
Open
1.8808
High
1.889
Low
1.7167
52 wk Range
1.711-9.69
Market Cap
98 468 K
Shares Outstanding
52 314 K
Revenue
2 816 K
EPS
-0.29
Beta
0.906
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Tscan Therapeutics Inc data using free add-ons & libraries
Get Tscan Therapeutics Inc Fundamental Data
Tscan Therapeutics Inc Fundamental data includes:
- Net Revenue: 2 816 K
- EBITDA: -130 713 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-05
- EPS/Forecast: -0.2752
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Tscan Therapeutics Inc News
New
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
WALTHAM, Mass., Feb. 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cel...
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
WALTHAM, Mass., Feb. 18, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cel...
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
TScan Therapeutics, Inc. New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029 WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan...
TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years
WALTHAM, Mass., Nov. 30, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
